What is Alnylam Pharmaceuticals's D&A?

Alnylam Pharmaceuticals (ALNY) reported D&A of $13.9M in Q2 2026.

How has Alnylam Pharmaceuticals's D&A changed year-over-year?

Alnylam Pharmaceuticals's D&A decreased by 0.3% year-over-year, from $13.94M to $13.9M.

What is the long-term trend for Alnylam Pharmaceuticals's D&A?

Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's D&A has grown at a 4.0% compound annual growth rate (CAGR), from $47.57M to $55.66M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Alnylam Pharmaceuticals ALNY D&A

D&A at other companies

Ionis PharmaceuticalsIONS

$3.43M+51.5%

Arrowhead ResearchARWR

$6.37M+4.7%

PTC TherapeuticsPTCT

$15.41M+113%

Assembly BiosciencesASMB

$26K-21.2%

Arbutus Biopharma CorporationABUS

$11K-96.7%

Wave Life SciencesWVE

$858K-0.8%

Other financials

Income statement

See full

Revenue$1.3B+66.9%

Gross profit$992.7M+57.2%

Operating income$231.4M+1,529%

Net income$164.5M+348%

EPS (diluted)$1.21+337%

Balance sheet

See full

Cash & equivalents$1.7B+53.2%

Total debt$256.4M-5.2%

Total equity$1.4B+440%

Total assets$5.6B+21.7%

Cash flow

See full

Operating cash flow$326.7M+113%

CapEx$34.7M+143%

Free cash flow$292.0M+109%

Valuation

See full

Market cap$38.51B-13.6%

Enterprise value$37.05B-15.3%

P/E52.5×—

P/S8×-10.1×

Profitability

See full

Gross margin79.8%-4.1pp

Operating margin20.8%+16.5pp

Net margin15.3%+10.7pp

FCF margin16.5%+14.8pp

Returns & leverage

See full

Return on equity91.4%—

Debt / equity0.2×-0.9×

Current ratio3.1×+0.3×

Where this comes from

Reported directly by Alnylam Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAmortizationAndAccretionNet.

The official record: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alnylam Pharmaceuticals's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Alnylam Pharmaceuticals's D&A?: Alnylam Pharmaceuticals (ALNY) reported D&A of $13.9M in Q2 2026.
How has Alnylam Pharmaceuticals's D&A changed year-over-year?: Alnylam Pharmaceuticals's D&A decreased by 0.3% year-over-year, from $13.94M to $13.9M.
What is the long-term trend for Alnylam Pharmaceuticals's D&A?: Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's D&A has grown at a 4.0% compound annual growth rate (CAGR), from $47.57M to $55.66M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.